Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Assets (2016 - 2025)

Historic Current Assets for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $402.7 million.

  • Adma Biologics' Current Assets rose 2654.43% to $402.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $402.7 million, marking a year-over-year increase of 2654.43%. This contributed to the annual value of $331.4 million for FY2024, which is 2894.68% up from last year.
  • Per Adma Biologics' latest filing, its Current Assets stood at $402.7 million for Q3 2025, which was up 2654.43% from $399.6 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Current Assets registered a high of $402.7 million during Q3 2025, and its lowest value of $171.4 million during Q2 2021.
  • Moreover, its 5-year median value for Current Assets was $266.2 million (2023), whereas its average is $270.2 million.
  • As far as peak fluctuations go, Adma Biologics' Current Assets soared by 3576.73% in 2021, and later crashed by 495.15% in 2023.
  • Quarter analysis of 5 years shows Adma Biologics' Current Assets stood at $208.7 million in 2021, then rose by 29.55% to $270.4 million in 2022, then dropped by 4.95% to $257.0 million in 2023, then increased by 28.95% to $331.4 million in 2024, then increased by 21.5% to $402.7 million in 2025.
  • Its Current Assets stands at $402.7 million for Q3 2025, versus $399.6 million for Q2 2025 and $351.8 million for Q1 2025.